ESC Congress 2003: Bone marrow cells to repair myocardial infarction. Are they really capable of replacing injured cells and reducing infarct size?August 31, 2003IMPORTANT: This press release accompanies a poster or oral session given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology ESC Congress 2003: The heart is incapable of cardiocell regeneration after myocardial infarction or other injuries. After an acute myocardial infarction, non contractile scar tissue will develop with regional malefunction which may finally result in heart failure. Present treatment options include recanalization of the occluded coronary vessel to reduce the amount of injured cells and tailored medical therapy for heart failure. So far, common treatment has been unable to replace the scar tissue by contracting myocardial cells. The new concept of cell transplantation has been addressed by two recent human investigations. Bone marrow cells of the patient are injected into the coronary circulation about one week after myocardial infarct to replace the injured cells and reduce the infarct size. This intervention seemed to be successful to reduce the contractile malefunction after myocardial infarction. The background of this observation is the new concept derived from animal experiments that some of adult bone marrow cells can home in the heart and then transdifferentiate to myocardial cells. Therefore, our goal in the present investigation was to repeat these clinical investigations in patients with large anterior myocardial infarcts. Once the patients came into the hospital with an acute myocardial infarct the occluded vessel was mechanically recanalized with a balloon catheter to restore the blood flow instantly and the occlusion area was protected with a coronary stent. Although blood flow is then re-established - due to the interruption of blood flow for several hours - many cells are dying and a myocardial scar is developing. Therefore, after 7 days 30 ml of bone marrow was drawn from a puncture of a hip bone and a certain subset of the cells (monocytic cells) were separated to a final volume of a about 8 - 10 ml containing 2.2 x 107 monocytic bone marrow cells. By a second catheterisation these cells were transferred into the coronary circulation over a balloon catheter into the injured tissue. The regional contractile force, the global contractile force and the regional coronary blood flow was measured at 3 month and 1 year after cell injection. Contradictory to the previous investigations, our experiments in large myocardial infarcts do not demonstrate regional or global contractile improvement at 3 month and 1 year. Therefore, the concept that patients bone marrow cells might replace injured myocardial cells and reduce infarct size can not be confirmed in patients with large myocardial infarctions. Prof. Dr. Med. Hans R. Figulla Friedrich-Schiller-University Jena, Germany European Society of Cardiology (ESC) |
|||||||||||||||||||||
| Related Bone Marrow Current Events and Bone Marrow News Articles Gene mismatch influences success of bone marrow transplants A commonly inherited gene deletion can increase the likelihood of immune complications following bone marrow transplantation, an international team of researchers reports in the November 22 advance online issue of Nature Genetics. New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Bone Implant Offers Hope for Skull Deformities A synthetic bone matrix offers hope for babies born with craniosynostosis, a condition that causes the plates in the skull to fuse too soon. U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. Scientists successfully reprogram blood cells Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome. Immune therapy can protect against or treat later lymphoma Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection. Stem cell therapy may offer hope for acute lung injury Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease. New insight in the fight against the Leishmania parasite Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated. 2-million-year-old evidence shows tool-making hominins inhabited grassland environments In an article published in the open-access, peer-reviewed journal PLoS ONE on October 21, 2009, Dr Thomas Plummer of Queens College at the City University of New York, Dr Richard Potts of the Smithsonian Institution National Museum of Natural History and colleagues report the oldest archeological evidence of early human activities in a grassland environment, dating to 2 million years ago. Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut. More Bone Marrow Current Events and Bone Marrow News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||